## Charlotte S Wilhelm-Benartzi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9540034/publications.pdf

Version: 2024-02-01



CHARLOTTE S

#	Article	IF	CITATIONS
1	Whole–genome characterization of chemoresistant ovarian cancer. Nature, 2015, 521, 489-494.	27.8	1,206
2	Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study. Gut, 2013, 62, 1764-1770.	12.1	330
3	Poised epigenetic states and acquired drug resistance in cancer. Nature Reviews Cancer, 2014, 14, 747-753.	28.4	252
4	Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene, 2012, 31, 4567-4576.	5.9	238
5	<i>In Utero</i> Exposures, Infant Growth, and DNA Methylation of Repetitive Elements and Developmentally Related Genes in Human Placenta. Environmental Health Perspectives, 2012, 120, 296-302.	6.0	174
6	Review of processing and analysis methods for DNA methylation array data. British Journal of Cancer, 2013, 109, 1394-1402.	6.4	164
7	Birthweight is associated with DNA promoter methylation of the glucocorticoid receptor in human placenta. Epigenetics, 2011, 6, 566-572.	2.7	148
8	Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer. Clinical Cancer Research, 2017, 23, 2213-2222.	7.0	83
9	The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer. Histopathology, 2014, 65, 340-352.	2.9	59
10	A model to predict vaginal delivery in nulliparous women based on maternal characteristics and intrapartum ultrasound. American Journal of Obstetrics and Gynecology, 2015, 213, 362.e1-362.e6.	1.3	54
11	Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review. British Journal of Cancer, 2012, 107, 1069-1074.	6.4	51
12	Epigenetic Regulation of the Homeobox Gene <i>MSX1</i> Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer. Clinical Cancer Research, 2016, 22, 3097-3104.	7.0	45
13	Association of secondhand smoke exposures with DNA methylation in bladder carcinomas. Cancer Causes and Control, 2011, 22, 1205-1213.	1.8	38
14	Radiological predictors of cytoreductive outcomes in patients with advanced ovarian cancer. BJOG: an International Journal of Obstetrics and Gynaecology, 2015, 122, 843-849.	2.3	38
15	Genes Predisposed to DNA Hypermethylation during Acquired Resistance to Chemotherapy Are Identified in Ovarian Tumors by Bivalent Chromatin Domains at Initial Diagnosis. Cancer Research, 2018, 78, 1383-1391.	0.9	35
16	Association of somatic DNA methylation variability with progression-free survival and toxicity in ovarian cancer patients. Annals of Oncology, 2013, 24, 2813-2818.	1.2	33
17	DNA methylation profiles delineate etiologic heterogeneity and clinically important subgroups of bladder cancer. Carcinogenesis, 2010, 31, 1972-1976.	2.8	29
18	Ultrasound is better tolerated than vaginal examination in and before labour. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2019, 59, 362-366.	1.0	25

CHARLOTTE S

#	Article	IF	CITATIONS
19	Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study. British Journal of Cancer, 2017, 116, 1287-1293.	6.4	22
20	Ambient Particulate Matter and the Response to Orthostatic Challenge in the Elderly. Hypertension, 2012, 59, 558-563.	2.7	21
21	Transcriptional implications of intragenic DNA methylation in the oestrogen receptor alpha gene in breast cancer cells and tissues. BMC Cancer, 2015, 15, 337.	2.6	16
22	Prediction of mode of delivery using the first ultrasound-based "intrapartum app― American Journal of Obstetrics and Gynecology, 2019, 221, 163-166.	1.3	15
23	Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia. Blood Advances, 2019, 3, 3052-3061.	5.2	15
24	Gestational length assignment based on last menstrual period, first trimester crown-rump length, ovulation, and implantation timing. Archives of Gynecology and Obstetrics, 2016, 294, 867-876.	1.7	13
25	Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer. British Journal of Cancer, 2021, 124, 581-586.	6.4	9
26	Challenges and methodology in the incorporation of biomarkers in cancer clinical trials. Critical Reviews in Oncology/Hematology, 2017, 110, 49-61.	4.4	8
27	NY-ESO-1 expression in DCIS: A new predictor of good prognosis. Oncoscience, 2017, 4, 33-40.	2.2	7
28	Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes. BMJ Open, 2021, 11, e053669.	1.9	4
29	The Impact of Focality and Centricity on Vulvar Intraepithelial Neoplasia on Disease Progression in HIV+ Patients: A 10-Year Retrospective Study. Dermatology, 2019, 235, 327-333.	2.1	3
30	Homologous recombination (HR) deficiency, tumor BRCA1/2 mutations (tmBRCA) and association with response and outcome following platinum monotherapy in high grade serous ovarian cancer (HGSOC) Journal of Clinical Oncology, 2015, 33, 5576-5576.	1.6	2